Clinical Trial Update: Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating the safety and efficacy of once-daily LCP-Tacro in stable kidney transplant recipients converted from twice-daily Progr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation
• Renal Failure

Drugs mentioned

• LCP-Tacro (tacrolimus)
• Prograf (Tacrolimus)

Snippet

Sponsor: Veloxis Pharmaceuticals | Conditions: Renal Failure | Phase 3 | Status: COMPLETED | Results posted: 2015-09-10